Cancer Treatment Today

After the great of success CAR T cell therapy in ALL, attention turned to its use in multiple myeloma. After the success of clinical trials, CAR T-cell therapy is approved for multiple myeloma that has relapsed after or is refractory to at least four prior treatments. The clinical trial showed the CAR T-cell therapy to be highly effective for patients whose disease had relapsed after or not responded to multiple prior treatments. The two CAR T-cell therapies approved by the FDA for treating multiple myeloma bind to the BCMA protein (blue) on the surface of myeloma cells.

On February 28, the Food and Drug Administration (FDA) approved ciltacabtagene autoleucel (Carvykti) for adults with multiple myeloma that is not responding to treatment (refractory) or has returned after treatment (relapsed). The approval was based on results from a small clinical trial in which cilta-cel reduced the amount of cancer in nearly every participant and, for many, kept their cancer in check for more than a year. Like the first FDA-approved CAR T-cell therapy for multiple myeloma, cilta-cel targets a protein on myeloma cells called BCMA.

Dimopoulos MA, Richardson PG, Moreau P, et al. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015;12:42-54.
Khalil DN, Smith EL, Brentjens RJ, et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13:273-290.
Themeli M, Rivière I, Sadelain M. New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell. 2015;16:357-366.
Carvykti, Prescribign Information 2022
Guo B, Chen M, Han Q, et al. CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma. J Cell Immun. 2016;2:28-35.
Ramos CA, Savoldo B, Torrano V, et al. Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J Clin Invest. 2016;126:2588-2596.